TME Pharma (France/Germany) announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for NOX-A12 (olaptesed pegol), TME Pharma’s CXCL12 inhibitor, in combination with radiotherapy and bevacizumab for use in the treatment of the aggressive adult brain cancer glioblastoma.

At a recent event researcher and founder of Bit.bio, Prof. Mark Kotter, Babraham Research Campus in Cambridge/UK, was asked what healthcare looks like in 2050. He gave a twofold answer, that it will be driven by data, but also will be personalised. Mark Kotter elaborates here in more detail what is needed to unlock a healthcare of tomorrow.

Connect with the world of fine and speciality chemicals: taking place from 19-20 June 2024 at the Messe Düsseldorf exhibition centre in Germany, Chemspec Europe is the key marketplace to showcase the full array of fine and speciality chemicals, bespoke ­solutions, services, and equipment.  

Forbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. Both companies are located in San Diego, USA.

Professionalism and quality are always at the forefront along the whole value chain: from gene to product. To pro-actively meet the evolving demand of the market to produce new assets Richter-Helm significantly increased its manufacturing capacities for biopharmaceutical products at its production site in Bovenau, Germany.

With a new law, the German government wants to increase the number of clinical trials conducted in Germany and make the country number one in Europe again.

A bacterium of the gut microbiome seems to spark an autoimmune disease in the kidneys by leaking antigens that trigger the immune system.

Cultivated meat producer Innocent Meat GmbH has cashed in €3m in funding from Venture Capital Fonds MV and an anonymous business angel.

Spanish Ferrer Internacional, SA has aquired the ex-US rights to VRG50635 from Verge Genomics Inc to commercialise the oral Phase I experimental ALS treatment.

Born with the aim of harmonising the application, evaluation, and supervision process of clinical trials conducted in EU countries, there is much room for improvement for the Clinical Trial Information System CTIS, particularly with regard to SMEs and translational researchers.